Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Mike I. Walton"'
Autor:
Michelle D. Garrett, Ian Collins, Paul Workman, Suzanne A. Eccles, Florence I. Raynaud, Wynne Aherne, Neil T. Thompson, John J. Caldwell, Gowri Vijayaraghavan, Lisa Pickard, Alan Henley, Simon P. Heaton, Ruth Ruddle, Paul D. Eve, Alexis de Haven Brandon, Melanie Valenti, Lisa-Jane K. Hunter, Mike I. Walton, Timothy A. Yap
Supplementary Figures 1-4 from Preclinical Pharmacology, Antitumor Activity, and Development of Pharmacodynamic Markers for the Novel, Potent AKT Inhibitor CCT128930
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::152e6b9e2a7c0fc3cf17558fd7b2c7b2
https://doi.org/10.1158/1535-7163.22496215.v1
https://doi.org/10.1158/1535-7163.22496215.v1
Autor:
Michelle D. Garrett, Ian Collins, Paul Workman, Suzanne A. Eccles, Florence I. Raynaud, Wynne Aherne, Neil T. Thompson, John J. Caldwell, Gowri Vijayaraghavan, Lisa Pickard, Alan Henley, Simon P. Heaton, Ruth Ruddle, Paul D. Eve, Alexis de Haven Brandon, Melanie Valenti, Lisa-Jane K. Hunter, Mike I. Walton, Timothy A. Yap
Supplementary Figure Legends and Supplementary Table 1 from Preclinical Pharmacology, Antitumor Activity, and Development of Pharmacodynamic Markers for the Novel, Potent AKT Inhibitor CCT128930
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::67936b34bb07aa265992163ae6426afc
https://doi.org/10.1158/1535-7163.22496218.v1
https://doi.org/10.1158/1535-7163.22496218.v1
Autor:
Michelle D. Garrett, Ian Collins, Paul Workman, Suzanne A. Eccles, Florence I. Raynaud, Wynne Aherne, Neil T. Thompson, John J. Caldwell, Gowri Vijayaraghavan, Lisa Pickard, Alan Henley, Simon P. Heaton, Ruth Ruddle, Paul D. Eve, Alexis de Haven Brandon, Melanie Valenti, Lisa-Jane K. Hunter, Mike I. Walton, Timothy A. Yap
AKT is frequently deregulated in cancer, making it an attractive anticancer drug target. CCT128930 is a novel ATP-competitive AKT inhibitor discovered using fragment- and structure-based approaches. It is a potent, advanced lead pyrrolopyrimidine com
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0ccf70ce5d4c987a11727e4158ff1adf
https://doi.org/10.1158/1535-7163.c.6535195.v1
https://doi.org/10.1158/1535-7163.c.6535195.v1
Autor:
Michelle D. Garrett, Ian Collins, Suzanne A. Eccles, Florence I. Raynaud, Louis Chesler, John C. Reader, G. Wynne Aherne, Simon P. Robinson, Yann Jamin, Thomas P. Matthews, Michael Lainchbury, Kathy J. Boxall, Elizabeth L. Smith, Albert Hallsworth, Gary Box, Alexis K. De Haven Brandon, Melanie R. Valenti, Angela Hayes, Paul D. Eve, Mike I. Walton
PDF file, 79K, Supplementary Table 3 - Mouse body weights for data in Figure 4A Body Weights expressed as a percentage of the weight on day 0 for mice bearing HT29 xenografts and treated with gemcitabine (100mg/kg iv), CCT244747 (75mg/kg po) or the c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::401ea57b719c1a1d93ab5881aa5484ab
https://doi.org/10.1158/1078-0432.22445615
https://doi.org/10.1158/1078-0432.22445615
Autor:
Michelle D. Garrett, Ian Collins, Suzanne A. Eccles, Florence I. Raynaud, Louis Chesler, John C. Reader, G. Wynne Aherne, Simon P. Robinson, Yann Jamin, Thomas P. Matthews, Michael Lainchbury, Kathy J. Boxall, Elizabeth L. Smith, Albert Hallsworth, Gary Box, Alexis K. De Haven Brandon, Melanie R. Valenti, Angela Hayes, Paul D. Eve, Mike I. Walton
PDF file, 92K, Supplementary Figure 2. A constrained, scaffold docking model of CCT244747 in the ATP pocket of human CHK1 realized using the SAR-020106 X-ray crystal structure (PDB 2ym8).
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9db6fcbdeb80531e3ddd7d42e0cafbdd
https://doi.org/10.1158/1078-0432.22445639
https://doi.org/10.1158/1078-0432.22445639
Autor:
Michelle D. Garrett, Neil T. Thompson, Paul Workman, Suzanne A. Eccles, Florence I. Raynaud, John F. Lyons, Thomas G. Davies, Steven J. Woodhead, Matthias Reule, Ruth E. Feltell, Paul S. Jones, Kathrin Heinzmann, Simon P. Heaton, Anna Zetterlund, Vanessa Martins, Alexis K. de Haven Brandon, Melanie R. Valenti, Paul D. Eve, Robert H. te Poele, Kyla M. Grimshaw, Mike I. Walton, Timothy A. Yap
PDF file - 81K, Supplementary data comprising the materials and methods for (i) crystallography (ii) gene expression studies (iii) siRNA studies and Supplementary Figure legends 1-7
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::136ef480c6dff64c10335140171ee9da
https://doi.org/10.1158/1078-0432.22446023.v1
https://doi.org/10.1158/1078-0432.22446023.v1
Autor:
Michelle D. Garrett, Ian Collins, Suzanne A. Eccles, Florence I. Raynaud, Louis Chesler, John C. Reader, G. Wynne Aherne, Simon P. Robinson, Yann Jamin, Thomas P. Matthews, Michael Lainchbury, Kathy J. Boxall, Elizabeth L. Smith, Albert Hallsworth, Gary Box, Alexis K. De Haven Brandon, Melanie R. Valenti, Angela Hayes, Paul D. Eve, Mike I. Walton
PDF file, 118K, Supplementary Table 2 Summary of Effects of Irinotecan, Gemcitabine and CCT244747 alone or in combination on human tumor xenografts growth delay.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2d1bd0e4da26aa07abae832d484513eb
https://doi.org/10.1158/1078-0432.22445618
https://doi.org/10.1158/1078-0432.22445618
Autor:
Michelle D. Garrett, Ian Collins, Suzanne A. Eccles, Florence I. Raynaud, Louis Chesler, John C. Reader, G. Wynne Aherne, Simon P. Robinson, Yann Jamin, Thomas P. Matthews, Michael Lainchbury, Kathy J. Boxall, Elizabeth L. Smith, Albert Hallsworth, Gary Box, Alexis K. De Haven Brandon, Melanie R. Valenti, Angela Hayes, Paul D. Eve, Mike I. Walton
PDF file, 810K, Supplementary Figure 3 Characterisation of the effects of minimally toxic concentrations of CCT244747 alone or in combination with genotoxic agents (+) in HT29 and SW620 colon cancer cell lines. A, HT29 cells were treated with SN38 (1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::343131448e94d2702194f9a5362972e1
https://doi.org/10.1158/1078-0432.22445636
https://doi.org/10.1158/1078-0432.22445636
Autor:
Michelle D. Garrett, Neil T. Thompson, Paul Workman, Suzanne A. Eccles, Florence I. Raynaud, John F. Lyons, Thomas G. Davies, Steven J. Woodhead, Matthias Reule, Ruth E. Feltell, Paul S. Jones, Kathrin Heinzmann, Simon P. Heaton, Anna Zetterlund, Vanessa Martins, Alexis K. de Haven Brandon, Melanie R. Valenti, Paul D. Eve, Robert H. te Poele, Kyla M. Grimshaw, Mike I. Walton, Timothy A. Yap
XLS file - 703K, Gene expression data for CCT128930: Genes that showed at least a 1.5 Fold Change in at least one treated sample compared to vehicle control and were differentially expressed between the treatment groups (Welch ANOVA FDR5%)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::264e5ae7347bb9dfece9541b75115729
https://doi.org/10.1158/1078-0432.22446017.v1
https://doi.org/10.1158/1078-0432.22446017.v1
Autor:
Michelle D. Garrett, Ian Collins, Suzanne A. Eccles, Florence I. Raynaud, Louis Chesler, John C. Reader, G. Wynne Aherne, Simon P. Robinson, Yann Jamin, Thomas P. Matthews, Michael Lainchbury, Kathy J. Boxall, Elizabeth L. Smith, Albert Hallsworth, Gary Box, Alexis K. De Haven Brandon, Melanie R. Valenti, Angela Hayes, Paul D. Eve, Mike I. Walton
PDF file, 67K, Supplementary Figure 4. Effects of scheduling and exposure times on the ability of two different CHK1 inhibitors to potentiate gemcitabine cytotoxicity in SW620 cells in vitro. A, Effect of different contact times on the capacity of SA
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::645f855fb751a0d3f4a65c2278c348bf
https://doi.org/10.1158/1078-0432.22445633.v1
https://doi.org/10.1158/1078-0432.22445633.v1